Trial Parameters
Condition Multiple Sclerosis
Sponsor Inés Llamas-Ramos
Study Type INTERVENTIONAL
Phase N/A
Enrollment 34
Sex ALL
Min Age 18 Years
Max Age 70 Years
Start Date 2024-11-04
Completion 2025-06-30
All Conditions
Interventions
Intrinsic Mucle Training
Brief Summary
The study tries to assess the efficacy of an 8-week IFM training programme on stability in patients diagnosed with Multiple Sclerosis
Eligibility Criteria
Inclusion Criteria: * Patients with moderate neurological disability as scored by the Expanded Disability Status Scale (EDSS), ranging from 3.0 to 6.0 Exclusion Criteria: * Cognitive disturbances that could affect the performance of any of the tests or questionnaires included in the study * Diagnosis of visual or vestibular disorders that could affect patient stability * Change in Multiple Sclerosis-specific medication in the 2 months prior to the start of the study * Acute relapse in the 2 months prior to the start of the study * Traumatologic or orthopaedic disorders that could negatively affect balance.
Related Trials
NCT07225361
Ublituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis
View Trial →
NCT05003388
Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusio
View Trial →
NCT03850301
Validation of the 18 kiloDalton Translocator Protein (TSPO) as a Novel Neuroimmunodulatory Target
View Trial →